Related Experiment Video
Updated: Jun 23, 2026
One-day Workflow Scheme for Bacterial Pathogen Detection and Antimicrobial Resistance Testing from Blood Cultures
Published on: July 9, 2012
Cefiderocol susceptibility rates in carbapenem-resistant Gram-negative bacteria in a comparative, multicenter
Yan Guo1, Shi Wu1, Weiwei Yang1
1Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China; Key Laboratory of Clinical Pharmacology of Antibiotics, Ministry of Health, Shanghai, China; Joint Laboratory of Hospital & Enterprise for Pathogen Diagnosis of Drug-resistant Bacterial Infections and Innovative Drug R&D, Shanghai, China.
Cefiderocol shows high susceptibility against most carbapenem-resistant Gram-negative bacteria in China, except for NDM-positive E. coli. Continuous monitoring of cefiderocol susceptibility is essential for effective treatment strategies.
Area of Science:
- Antimicrobial Resistance
- Infectious Diseases
- Clinical Microbiology
Background:
- Cefiderocol is a novel siderophore cephalosporin effective against carbapenem-resistant (CR) Gram-negative bacteria.
- CR Gram-negative infections pose a significant threat in healthcare settings.
Purpose of the Study:
- To evaluate cefiderocol susceptibility among CR Gram-negative pathogens from hospitalized patients in China.
- To compare cefiderocol activity with other antibiotics against these challenging pathogens.
Main Methods:
- Broth microdilution method following Clinical and Laboratory Standards Institute (CLSI) guidelines.
- Molecular characterization of carbapenemase genes (OXA-48, IMP, KPC, NDM) using whole-genome sequencing and PCR.
- Breakpoints from CLSI, US FDA, and European Committee on Antimicrobial Susceptibility Testing were used.
Main Results:
- Cefiderocol demonstrated high susceptibility (≥88%) against most CR Gram-negative isolates, including CR Klebsiella pneumoniae (95.3%), CR Pseudomonas aeruginosa (98.4%), and CR Acinetobacter baumannii (99.6%).
- Lower susceptibility was observed for NDM-positive CR Escherichia coli (45.6%).
- Ceftazidime-avibactam showed limited activity, while colistin maintained high activity against CR Pseudomonas aeruginosa and CR Acinetobacter baumannii.
Conclusions:
- Cefiderocol is a promising option for treating infections caused by various CR Gram-negative bacteria in China.
- NDM-producing CR E. coli represent a challenge for cefiderocol therapy.
- Ongoing surveillance of cefiderocol susceptibility is crucial to guide clinical practice.